Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnosis of IPMN using duodenal lavage fluid with synthetic human secretin and dedicated catheter
jRCTs051230154Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of secretin in intraductal papillary mucinous neoplasm (IPMN), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Sensitivity and specificity of duodenal lavage fluid-based test for IPMN grading. Started Jan 2024; status: recruiting.
02
Drugs
secretin
03
Conditions
intraductal papillary mucinous neoplasm (IPMN)
Beyond the preview
Go deeper on jRCTs051230154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230154.